德国新冠疫苗厂商受限于美国出口管制，难以获得原料
来看看什么叫口惠而实不至。
德国另一家研究mRNA的疫苗厂商CureVac，背景是德国政府、英国GSK和盖茨基金会，新冠疫苗合作厂商还包括老牌药企拜耳，合作方包括英国政府，可谓豪华。
新冠疫苗进展也算顺利，目前在欧洲、拉美进行的超4万人入组的大型临床试验入组已经完全结束，预计2季度就会有结果出来。
即便老牌发达国家、大药企支持，不缺技术，不缺产能，但4号接受路透采访说，由于原材料受到美国国防法案限制，难以获得，无法预估后续生产量。
https://news.yahoo.com/curevac-says-mass-vaccine-rollout-144023804.html
·2 min read
BERLIN (Reuters) - Germany's CureVac, which is gearing up to publish results of a key COVID-19 vaccine trial, said U.S. export restrictions on key materials are making it impossible to predict its short-term supply ramp-up in Europe.
"Due to the Defense Production Act we are not getting certain goods out of the USA," CureVac Chief Executive Franz-Werner Haas told weekly Der Spiegel.
The Defense Production Act is a decades old U.S. law that gives federal agencies the power to prioritize procurement orders related to national defence, but it has also widely been used in non-military crises such as natural disasters.
"We are not getting all the materials that we need," he was quoted as saying.
"At times we live from hand to mouth. That makes it hard to build up a stockpile," Haas said, when asked how much the company would be able to deliver during the summer months.
He added that items in short supply include special plastic containers and nucleotides, which are the chemical building blocks that make up the genetic code in the vaccine's active ingredient, the so-called messenger RNA.
可想而知，口惠的所谓开放专利有多大机会能达成？细读一下表态本身就很模棱两可——“supports the waiver of those protections for COVID-19 vaccines. We will actively participate in text-based negotiations at the WTO needed to make that happen.”
只是一个姿态，象征意义更大，WTO里边吵上几年，可能也就不了了之。即便放开专利，发展中国家普遍也没有能力生产，更多是发展中国家作为一个议题，争取更便宜的疫苗吧。
现在整个疫苗供应的瓶颈不在专利，而在于供应链。美国优先不是戏言，仆从国日、加才拿到多少苗？也就这周美国才刚刚开始供应点给加拿大。
听其言，更要观其行，真不必把美国想的太好了。